SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to a mixed earnings report, with a Q4 beat overshadowed by a weaker-than-expected Q1 outlook, leading to a significant immediate share price pullback. The community is actively debating whether this represents an overreaction and a buying opportunity or reflects deeper competitive challenges and a lengthy turnaround for its foundry business. This discussion highlights the ongoing scrutiny of Intel's position within the rapidly evolving semiconductor landscape.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune (ALT) is experiencing heightened trading activity and community discussion, largely fueled by its Breakthrough Therapy Designation for pemvidutide and escalating rumors of a potential buyout or partnership deal. This has led to a deeply divided investor sentiment, with bulls anticipating a significant re-rating in the competitive GLP-1/MASH sector, while skeptics point to historical challenges and ongoing legal concerns.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending due to reports of an imminent TikTok US spinoff deal, which includes Oracle, fueling speculation about its expanded role in social media data hosting. This development intensifies the ongoing debate among investors regarding Oracle's long-term growth from its significant AI and cloud infrastructure buildouts. The community is actively discussing whether the TikTok news will serve as a strong catalyst for a rebound or if concerns over the company's substantial debt and market skepticism will lead to a "sell the news" reaction.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is actively trending due to significant community speculation driven by its ultra-low share float, with many anticipating a substantial short squeeze and rapid price movement. While some highlight its cash-heavy balance sheet and ongoing strategic review, a strong cautionary sentiment exists, with traders debating the high risk associated with the company's announced discontinuation of its lead drug candidate and exploration of winding down operations versus a potential speculative breakout.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is currently trending amid widespread speculation that its lightweight, flexible solar technology is poised for critical roles in the expanding space sector, particularly for advanced orbital applications. Community discussions highlight enthusiasm following insights from influential figures about the future of space-based AI data centers and defense projects, alongside persistent chatter about high short interest and potential for significant moves. Traders are actively debating the company's strategic partnerships and its historical volatility, seeking clarity on future prospects.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano (MOVE) is trending due to news of its all-stock merger with AI cloud computing firm Corvex, which recently secured a long-term NVIDIA H200 GPU deployment, fueling immense speculation around its low float. The community is sharply divided, with many anticipating significant upside driven by AI sector excitement, while others express caution about potential dilution and the stock's historical volatility.

BitGo Holdings, Inc. provides cryptocurrency custody solutions. It offers self-custody wallet, qualified custody, liquidity and prime, and infrastructure-as-a-service. The company was founded by Michael Belshe in 2013 and is headquartered in Palo Alto, CA.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGo is trending following its NYSE debut as the first crypto IPO of the year, opening above its initial offering price. Community discussion is split, with some anticipating a significant run due to its large assets under management and high revenue growth, while others are wary of its initial volatility and drawing comparisons to past struggling crypto debuts amidst broader market conditions.

RYVYL Inc. is a financial technology company that develops software platforms and tools that are focused on providing global payment acceptance and disbursement capabilities. It offers an innovative payment platform-as-a-service that redefines global payment solutions, enabling seamless business-to-business, consumer-to-business, and peer-to-peer transactions worldwide. The company leverages advanced electronic payment technology to deliver seamless financial solutions across global markets. It operates through two geographical segments: North America and International. The company was founded on April 10, 2007 and is headquartered in San Diego, CA.

Ryvyl Inc

Ryvyl Inc. is gaining significant attention amid its pending merger with Roundtable, which aims to create a Web3 digital media platform leveraging a Bitcoin treasury. The community is actively discussing the recent reverse stock split and anticipated Nasdaq compliance, with many anticipating a potential short squeeze due to the extremely low public float. This confluence of developments in fintech and digital media is driving high conversation around the stock's future valuation and momentum.

Spring Valley Acquisition Corp. III is a blank check company. It was created for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on March 12, 2025 an is headquartered in Dallas, TX.

Spring Valley Acquisition Corp III - Ordinary Shares - Class A

SVAC is trending rapidly following its business combination with General Fusion, poised to become the first publicly traded pure-play fusion energy company. The community is buzzing with excitement over the long-term potential of this groundbreaking technology, drawing attention to prominent backers like Jeff Bezos and the sponsor's successful track record with other energy SPACs. Many investors are viewing this as an early opportunity in the evolving nuclear energy landscape.

iOThree Ltd. is a holding company, which engages in the business of satellite communications and software. It operates through the Satellite Connectivity Solution and Digitalization and Other Solutions segments. The Satellite Connectivity Solution segment offers integrated satellite connectivity solutions through the provision of satellite connectivity services and the sale and lease of satellite network equipment and devices for shipboard network management. The Digitalization and Other Solutions segment is involved in designing digital solutions and providing information technology support and shipboard support services for IT and OT applications enablement. The company was founded by Eng Chye Koh on August 21, 2023 and is headquartered in Singapore.

iOThree Ltd

iOThree Limited Ordinary Shares

IOTR is trending after its v.secure system achieved IACS UR E27 Type Approval from RINA, sparking immediate community interest. As a low-float, Singapore-based company, it is generating significant discussion around potential rapid price movements and short squeezes, though some investors caution against its history of sharp pullbacks following notable gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax (NVAX) Stock Dips While Market Gains: Key Facts

In the latest trading session, Novavax (NVAX) closed at $9.71, marking a -1.97% move from the previous day.

<ul class="summary-bullets"><li>Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year.</li><li>Moderna was in focus after updated cancer vaccine data, while Novavax drew attention following its Pfizer licensing deal.</li><li>Retail sentiment on Stocktwits was 'extremely bullish' for both stocks, with message activity sharply higher over the past year.</li></ul>Wall Street is&nbsp;a bit&nbsp;split on Moderna and Novavax, with analysts favoring upside in one name even as the other has outperformed over the past year.<h2 class="st-heading-2">Analysts Favor Novavax Over Moderna</h2>Koyfin data shows analysts assigning greater upside to Novavax than Moderna based on consensus price targets.Moderna shares were last trading around $49.81 on Wednesday, but Wall Street’s expectations remain cautious. The stock’s average 12-month price target is $37.40, a 25% downside from current levels. Among the 24 analysts covering the company, the overall view sits at ‘Hold’, with two ‘Strong Buy’, two ‘Buy’, 17 ‘Hold’, one ‘Sell’, and two ‘Strong Sell’ ratings, giving Moderna an overall ‘Hold’ rating.Meanwhile, Novavax last closed at $9.9 on Wednesday, and analysts see room for gains. The stock’s average 12-month price target of $12.89 points to a 30% upside&nbsp;from current levels. Among the nine analysts tracking the company, five rate it ‘Buy’, one ‘Hold’, one ‘Sell’, and two ‘Strong Sell’, giving Novavax an overall ‘Buy’ rating.Over the past 12 months,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax shares</a>&nbsp;have been up about 12%, while&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> has gained roughly 39%.<h2 class="st-heading-2">Moderna Faces Analyst Caution</h2>On Tuesday,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-still-worth-37-less-after-cancer-vaccine-data-bof-a-s-new-price-target-keeps-retail-traders-cautious/cmUDauIR4OV">Bank of America Securities raised its price target to $27 from $24</a> while keeping an ‘Underperform’ rating, implying a 37% downside based on the stock’s prior close near $43.The update followed the release of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">five-year follow-up data</a> for Moderna’s personalized cancer vaccine Intismeran Autogene, developed with Merck and used alongside Keytruda in patients with high-risk melanoma. Moderna and Merck said patients receiving the combination showed a 49% lower risk of cancer recurrence or death compared with Keytruda alone.&nbsp;Earlier this month, UBS downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $34 from $40, implying about 32% downside from its last close.&nbsp;Moderna expects regulatory approvals this year for a standalone flu vaccine and a COVID-19/flu combination shot, though not in time for the 2026 respiratory season, with a potential boost in 2027. The company also expects key trial data in 2026, including late-stage norovirus results and mid-stage melanoma data.&nbsp;<h2 class="st-heading-2">Novavax In Focus</h2>This week, Novavax&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nvax-stock-rising-premarket-pfizer-matrix-m-deal/cmUumrjR4aq">signed a non-exclusive licensing deal with Pfizer</a> for up to two disease areas using its Matrix-M adjuvant. The deal includes a $30 million upfront payment, as well as the possibility of up to $500 million in development and sales milestones, and tiered royalties in the high mid-single-digit range.&nbsp;That deal followed Novavax handing over U.S. and European rights to its Covid-19 vaccine candidate Nuvaxovid to Sanofi in November for undisclosed upfront payments and possible milestones. The deal also opens the door&nbsp;to future royalties. Novavax also has deals with Takeda and the Serum Institute of India.Novavax has pushed its profitability target to 2028 as Covid-19 vaccine demand remains under pressure, while activist investor Shah Capital, which holds about 8.3%, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-stock-faces-retail-backlash-as-shah-capital-warns-of-proxy-fight-and-presses-for-a-sale/cLPBFk7REdt">urged the board to review strategic alternatives</a>, including a potential sale.<h2 class="st-heading-2">Regulatory Backdrop</h2>Uncertainty over regulatory approval also looms for both companies. Shares of Moderna and Novavax fell in December after an FDA memo to staff, which did not name a manufacturer, warned of safety problems with vaccines that could lead to tougher approval standards.Novavax’s COVID-19 vaccine has full FDA approval with age- and risk-level-based restrictions, while Moderna's COVID-19 vaccines have full licensure across broader age groups.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment toward Moderna was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 3% and message activity more than doubling over the past 12 months.<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_124327497e.webp" alt="mrna ss.png" width="971" height="142"><figcaption>MRNA sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure>On the other hand, retail sentiment toward Novavax was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 5% and message activity surging more than 600% over the past 12 months.<figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_ec285c2653.webp" alt="nvax ss.png" width="969" height="138"><figcaption>NVAX sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine safety.

Equity

Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX - Get Free Report) saw unusually large options trading activity on Wednesday. Investors acquired 24,027 call options on the stock. This represents an increase of...

Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer

NVAX inks a non-exclusive Matrix-M license, securing $30M upfront, up to $500M in milestones and mid-single-digit royalties from Pfizer.

Novavax (NASDAQ:NVAX) Stock Price Up 8% - Still a Buy?

Novavax (NASDAQ:NVAX) Trading Up 8% - Should You Buy...

Novavax's (NVAX) Buy Rating Reiterated at BTIG Research

BTIG Research restated a "buy" rating and issued a $19.00 price objective on shares of Novavax in a research report on Tuesday...

Novavax Shares Rise After Licensing Deal With Pfizer

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for Matrix-M adjuvant.read more...

<ul class="summary-bullets"><li>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones.</li><li>Matrix-M adjuvant is a proprietary vaccine ingredient, used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets.</li><li>Novavax is eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.</li></ul>Novavax, Inc. (NVAX) shares climbed 6% higher in pre-market trading on Tuesday after the company signed a licensing agreement with Pfizer, granting the pharmaceutical giant non-exclusive rights to use Novavax’s Matrix-M adjuvant in up to two disease areas.Matrix-M adjuvant is a proprietary vaccine ingredient that improves the body’s immune response. It is made from naturally derived compounds and is used in several marketed vaccines to improve effectiveness and help the immune system better recognize and remember disease targets, according to Novavax.<h2 class="st-heading-2">What Is The Novovax-Pfizer Deal?</h2>The deal provides Novavax with an upfront payment of $30 million, along with the opportunity to earn up to $500 million in additional development and sales milestones. Novavax is also eligible to receive tiered royalties in the high mid-single digit range on sales of any Pfizer products that use Matrix-M.Under the agreement, Pfizer will take full responsibility for the development and commercialization of its products, while Novavax will supply the Matrix-M adjuvant. The partnership strengthens Novavax’s long-term revenue potential.This comes after Novavax completed the transfer of U.S. and European marketing authorizations for its COVID-19 vaccine, Nuvaxovid, to Sanofi in November. The move resulted in a second $25 million milestone payment to Novavax, following the completion of the European Union marketing authorization transfer in October 2025.Novavax is expected to receive additional milestone payments and royalties tied to Nuvaxovid, Sanofi-developed combination products, and new vaccines that use Novavax’s Matrix-M adjuvant. Novavax also has long-standing partnerships with Japan’s Takeda and the Serum Institute of India.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/NVAX">NVAX</a> on Stocktwits remained in the ‘extremely bullish’ zone, amid ‘extremely high’ message volumes. NVAX was also among the top three trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/NVAX_jpg_1f4183eedd.webp" alt="NVAX.jpg">One bullish user said that the stock is undervalued.<stembedurl>https://stocktwits.com/ejaXstoXX/message/642272237</stembedurl>Another user was bullish about Matrix-M’s market potential.<stembedurl>https://stocktwits.com/P38FTD/message/642271830</stembedurl>The stock has declined around 6% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-ivf-stock-soaring-premarket/cmUum0oR4ap">INVO Fertility’s 350% Spike Puts Microcap IVF Stocks Back On Retail Radar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It?

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology

Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms of the agreement...

Novavax Announces Entering into a License Agreement with Pfizer

Novavax Announces Entering into a License Agreement with Pfizer Novavax Announces Entering into a License Agreement with Pfizer PR Newswire GAITHERSBURG, Md., Jan. 20, 2026 Non-exclusive license...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Adding shares on dips

Holding, no changes

Trading calls/puts

Watching only

$NVAX is trending hard after the Pfizer licensing headline, but price action is still choppy. What’s your move from here?

How are you playing $NVAX after the $PFE / Matrix-M deal?

Stocktwits

Novavax Inc

Pfizer Inc

Stocktwits Polls

Traders are actively discussing a potential short squeeze with high short interest (55M shares) and the exhaustion of borrowable shares, predicting an explosive upward movement.

Excitement surrounds Matrix-M adjuvant technology, with its recent validation by Pfizer suggesting its potential to become a standard, highly effective component in many future vaccines.

Traders are reacting to Moderna's decision to halt Phase 3 vaccine trials, speculating that mRNA technology is losing favor and positioning NVAX as a key player in the vaccine market.

Discussions highlight the significance of recent deals with Pfizer and Sanofi, with users eagerly anticipating further strategic partnerships for vaccine development and combination products.

Mixed sentiment surrounds CEO John Jacobs, with some criticizing his impact on stock price and communication, while others acknowledge recent partnership wins and anticipate future "surprises."

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVAX News

NVAXNovavax Inc